1-9 of 9
Maika Onishi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multiple Myeloma Disease Model to Predict PFS Outcomes across Lines of Therapy, an Analysis Based on Commpass Observational Study

Pascal Chanu, Sandhya Balasubramanian, Divya Samineni, Monica Susilo, Maika Onishi, Felipe A Castro, Madlaina Breuleux, Jin Jin, Chunze Li, René Bruno
Journal: Blood
Blood (2023) 142 (Supplement 1): 4711.
https://doi.org/10.1182/blood-2023-187678
Published: 2023
Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Clinical Trials & Observations
Naval G. Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen W. L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G. Ott, Wan-Jen Hong, Marina Y. Konopleva, Michael Andreeff
Journal: Blood
Blood (2023) 141 (11): 1265–1276.
https://doi.org/10.1182/blood.2022016362
Published: 2023
Includes: Supplemental data
Journal Articles

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco J. Bautista Sirvent, Valeria Ceolin, Bianca F. Goemans, Marlous Bakker, Laura Di Laurenzio, Jennifer Lukin, Harm Van Tinteren, Gauri B. Sunkersett, Maika Onishi, Kristina Unnebrink, Dirk Reinhardt, Gwen L Nichols, E. Anders Kolb, C. Michel Zwaan
Journal: Blood
Blood (2022) 140 (Supplement 1): 3369–3370.
https://doi.org/10.1182/blood-2022-168818
Published: 2022
Journal Articles

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Pankit Vachhani, Jonathan A. Abbas, Evelyn M. Flahavan, Esprit Ma, Tao Xu, Huan Jin, Melissa Montez, Weize Huang, Anda Gershon, Grace Ku, Brannon Flores, Maika Onishi, Cat N. Bui, William Donnellan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2290.
https://doi.org/10.1182/blood-2021-147851
Published: 2021
Journal Articles

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau
Journal: Blood
Blood (2021) 138 (Supplement 1): 84.
https://doi.org/10.1182/blood-2021-145757
Published: 2021
Journal Articles

Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)

Aparna Raval, Habib Hamidi, Olivia Hwang, Cherie Green, Catarina Maia, Marta Lasa, Maika Onishi, Paula Rodriguez-Otero, Jesús F. San-Miguel, Jorge D. Gallo, Bruno Paiva, PhD, Fredrik Schjesvold, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-134910
Published: 2020
Journal Articles

Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma

Fredrik Schjesvold, Vincent Ribrag, MD, Paula Rodriguez-Otero, MD PhD, Pawel J. Robak, MDPhD, Markus Hansson, MD, Roman Hajek, Adrián Alegre Amor, MD PhD, Joaquin Martinez-López, Maika Onishi, Jorge D. Gallo, Aparna Raval, Sameer Deshpande, Vikram Malhi, Wan-Jen Hong, MD, Marc S. Raab, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-135845
Published: 2020
Journal Articles

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Naval G. Daver, MD, Jacqueline S Garcia, MD, Brian A Jonas, MD PhD, Kevin R Kelly, MD PhD, Sarit Assouline, MD, Joseph M Brandwein, MD, Pierre Fenaux, MD PhD, Rebecca L. Olin, MD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Arnaud Pigneux, Daniel A Pollyea, MD, Bayard L Powell, MD, Gail J. Roboz, MD, Agostino Tafuri, MD, Norbert Vey, MD PhD, Giuseppe Visani, MD, Karen W.L. Yee, MD, Monique Dail, PhD, Cherie Green, BS, Whitney P Kirschbrown, PharmD, PhD, Wan-Jen Hong, MD, Marion G Ott, MD PhD, Maika Onishi, MD, Jue Wang, PhD, Marina Y Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 229.
https://doi.org/10.1182/blood-2019-123711
Published: 2019
Journal Articles

Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status

Maika Onishi, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, Karen Schiavo, ARNP, Mary Philip, MD, PhD, Edward N. Libby, III, MD, Ryan D. Cassaday, MD, John M. Pagel, MD, PhD, David G. Maloney, MD, PhD, Damian J. Green, MD, Brian G. Till, MD, Oliver W. Press, MD, PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2013) 122 (21): 2106.
https://doi.org/10.1182/blood.V122.21.2106.2106
Published: 2013